MLP SE

  • WKN: 656990
  • ISIN: DE0006569908
  • Land: Deutschland

Nachricht vom 01.10.2021 | 19:16

MLP SE: MLP SE anticipates to significantly exceed its own EBIT forecast for 2021, as well as to record significantly higher Q3 EBIT for 2021 than in the previous year

MLP SE / Key word(s): Forecast/Change in Forecast
MLP SE: MLP SE anticipates to significantly exceed its own EBIT forecast for 2021, as well as to record significantly higher Q3 EBIT for 2021 than in the previous year

01-Oct-2021 / 19:16 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


In the third quarter of 2021, MLP SE recorded significantly higher performance-based compensation than previously projected. With positive overall performance in its consulting fields, the MLP Group therefore anticipates to significantly exceed its current EBIT forecast for 2021 (upper end of the corridor from EUR 55 to 61 million), as well as to record significantly higher EBIT for Q3 2021 than in the same period of the previous year (Q3 2020: EUR 8.1 million).

Performance-based compensation is accrued for the positive performance of investment concepts in wealth management and is largely recognised in income. The sales revenue effect of the performance-based compensation in the third quarter of 2021 is around EUR 17 million. In the same period of the previous year (Q3 2020), MLP recorded a sales revenue effect from performance-based compensation of EUR 8.0 million.

Based on the successful business development recorded in the first half of 2021, MLP has already specified its EBIT forecast for the financial year 2021 on August 12, 2021, stating that it would probably reach the upper end of the announced corridor of EUR 55 to 61 million.

MLP will report the full financial figures for the third quarter of 2021 on November 11 as scheduled.

Performance-based compensation and EBIT represent alternative KPIs, which are described in further detail at:

https://mlp-se.com/investors/mlp-share/key-figures/

Contact/notifying person:
Jan Berg
Head of Corporate Communications
Tel: +49 (0)6222 308 4595
E-mail: jan.berg@mlp.de


01-Oct-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021